| Dir : /home/ithome/mail/new/ |
| Server: Linux host100322.itwesthosting.com 3.10.0-1160.144.1.el7.tuxcare.els4.x86_64 #1 SMP Tue Apr 7 08:40:40 UTC 2026 x86_64 IP: 144.91.64.173 |
| Dir : /home/ithome/mail/new/1773163361.M832137P13807.host100322.itwesthosting.com,S=7357,W=7482 |
Return-Path: <pharpharmacol@scienlist.com>
Delivered-To: ithome@host100322.itwesthosting.com
Received: from host100322.itwesthosting.com
by host100322.itwesthosting.com with LMTP
id UM15MWFTsGnvNQAAp0YrwQ
(envelope-from <pharpharmacol@scienlist.com>)
for <ithome@host100322.itwesthosting.com>; Tue, 10 Mar 2026 18:22:41 +0100
Return-path: <pharpharmacol@scienlist.com>
Envelope-to: senka.rendulic@bolnica-lipik.hr
Delivery-date: Tue, 10 Mar 2026 18:22:41 +0100
Received: from smtp.scienlist.com ([213.199.48.44]:33280)
by host100322.itwesthosting.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.96.2)
(envelope-from <pharpharmacol@scienlist.com>)
id 1w00n3-0003cy-34
for senka.rendulic@bolnica-lipik.hr;
Tue, 10 Mar 2026 18:22:41 +0100
Received: from [127.0.0.1] (localhost [127.0.0.1]) by localhost (Mailerdaemon) with ESMTPSA id 4563FCB282
for <senka.rendulic@bolnica-lipik.hr>; Wed, 11 Mar 2026 02:22:40 +0900 (JST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=scienlist.com;
s=dkim; t=1773163360;
h=from:reply-to:subject:date:message-id:to:mime-version:content-type;
bh=kl6Jz6nhJSOxdO2rQ+hkp4mhkOvqpQMHouLKGbgEDB4=;
b=Vx/Ey/fDNpMtec5Y9mxomdoGpk1Dxcv8qkIeXedROvZjl2Nuo0QcYpMGqoyHrhglssq9AB
8m9JYLUpGRxMsxK3MSLHU+dgIEwXrQ0vok1myLzCfcPFTa3jQ7sSKQ9u/+rXLqpDuYclxo
JFvYY2KeaM0Vcr5W7dLa2+o3WwY2bZZU8ZlsbfMT7j+KKDfNc+1SW9hvH4TMKxmb2HoifP
4HlPpSKSXyDbECyRrCCkLbL7fWmY9BVDHHMhSofSN1dajZRObUX+05dNehY5MVnob3a9ZG
2lyn+b8h2K+PDKEkgG7uLf1QtuRql25qM1uTGRCroLtT/M8m3L33gSpXifYCrA==
Date: Tue, 10 Mar 2026 17:22:40 +0000
To: senka.rendulic@bolnica-lipik.hr
From: David Marks <pharpharmacol@scienlist.com>
Reply-To: david.marks@fortunejournals.com
Subject: Re: Disease Activity, Inflammation Ma
Message-ID: <UA5DpZSqzMWi8Hljn2LNiGYEwwNk5Kw7y7MgYJa9PY@vmi2959108>
MIME-Version: 1.0
Content-Type: multipart/alternative;
boundary="b1=_UA5DpZSqzMWi8Hljn2LNiGYEwwNk5Kw7y7MgYJa9PY"
X-Last-TLS-Session-Version: TLSv1.3
X-Spam-Status: No, score=-0.2
X-Spam-Score: -1
X-Spam-Bar: /
X-Ham-Report: Spam detection software, running on the system "host100322.itwesthosting.com",
has NOT identified this incoming email as spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
root\@localhost for details.
Content preview: Hi,Season's greetings.We recently had the opportunity to read
your published article "Â Disease Activity, Inflammation Markers, and Quality
of Life Are Associated with Muscle Strength in Croatian Rheu [...]
Content analysis details: (-0.2 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was
blocked. See
http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block
for more information.
[URIs: research.in]
-0.0 SPF_PASS SPF: sender matches SPF record
0.0 RCVD_IN_VALIDITY_RPBL_BLOCKED RBL: ADMINISTRATOR NOTICE: The
query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[213.199.48.44 listed in bl.score.senderscore.com]
0.0 HTML_MESSAGE BODY: HTML included in message
-0.1 DKIM_VALID Message has at least one valid DKIM or DK signature
-0.1 DKIM_VALID_EF Message has a valid DKIM or DK signature from
envelope-from domain
0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily
valid
-0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from
author's domain
0.0 RCVD_IN_VALIDITY_CERTIFIED_BLOCKED RBL: ADMINISTRATOR NOTICE:
The query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[213.199.48.44 listed in sa-accredit.habeas.com]
X-Spam-Flag: NO
X-From-Rewrite: unmodified, forwarded message
--b1=_UA5DpZSqzMWi8Hljn2LNiGYEwwNk5Kw7y7MgYJa9PY
Content-Type: text/plain; charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Hi,Season's greetings.We recently had the opportunity to read your publishe=
d article "=C2=A0Disease Activity, Inflammation Markers, and Quality of Lif=
e Are Associated with Muscle Strength in Croatian Rheumatoid Arthritis Pati=
ents=E2=80=94A National-Based Study=C2=A0" and found it to be a well-struct=
ured and scientifically meaningful contribution. The scope and depth of you=
r study align closely with the focus of the=C2=A0Journal of Pharmacy and Ph=
armacology Research.In light of your expertise, I would like to invite you =
to=C2=A0consider submitting a new or related manuscript.The journal is inde=
xed in=C2=A0PubMed/PMC and holds an Impact Factor of 3.3. Our editorial pro=
cess emphasizes constructive peer review and timely decisions, with the goa=
l of supporting authors while maintaining high scientific standards.Should =
you wish to explore this opportunity, I would be glad to provide further de=
tails regarding submission and review.Thank you for your time, and I look f=
orward to your response.Kind regards,David Marks
--b1=_UA5DpZSqzMWi8Hljn2LNiGYEwwNk5Kw7y7MgYJa9PY
Content-Type: text/html; charset=UTF-8
Content-Transfer-Encoding: quoted-printable
<p data-start=3D"58" data-end=3D"81">Hi,</p><p data-start=3D"83" data-end=
=3D"104">Season's greetings.</p><p data-start=3D"106" data-end=3D"380">We r=
ecently had the opportunity to read your published article " <b>Diseas=
e Activity, Inflammation Markers, and Quality of Life Are Associated with M=
uscle Strength in Croatian Rheumatoid Arthritis Patients=E2=80=94A National=
-Based Study</b> " and found it to be a well-structured and scientific=
ally meaningful contribution. The scope and depth of your study align close=
ly with the focus of the <em data-start=3D"330" data-end=3D"377"><b>Jo=
urnal of Pharmacy and Pharmacology Research</b></em>.</p><p data-start=3D"3=
82" data-end=3D"589">In light of your expertise, I would like to invite you=
to <b>consider submitting a new or related manuscript.</b></p><p data=
-start=3D"591" data-end=3D"825">The journal is indexed in <b>PubMed/PM=
C and holds an Impact Factor of 3.3</b>. Our editorial process emphasizes c=
onstructive peer review and timely decisions, with the goal of supporting a=
uthors while maintaining high scientific standards.</p><p data-start=3D"827=
" data-end=3D"949">Should you wish to explore this opportunity, I would be =
glad to provide further details regarding submission and review.</p><p data=
-start=3D"951" data-end=3D"1014">Thank you for your time, and I look forwar=
d to your response.</p><p class=3D"isSelectedEnd"></p><p data-start=3D"1016=
" data-end=3D"1113" data-is-last-node=3D"" data-is-only-node=3D"">Kind rega=
rds,<br data-start=3D"1029" data-end=3D"1032">David Marks</p>
--b1=_UA5DpZSqzMWi8Hljn2LNiGYEwwNk5Kw7y7MgYJa9PY--